» Articles » PMID: 33684624

μ Opioid Antagonist Naltrexone Partially Abolishes the Antidepressant Placebo Effect and Reduces Orbitofrontal Cortex Encoding of Reinforcement

Overview
Date 2021 Mar 8
PMID 33684624
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Like placebo analgesia, the antidepressant placebo effect appears to involve cortical and subcortical endogenous opioid signaling, yet the mechanism through which opioid release affects mood remains unclear. The orbitofrontal cortex (OFC)-which integrates various attributes of a stimulus to predict associated outcomes-has been implicated in placebo effects and is rich in μ opioid receptors. We hypothesized that naltrexone blockade of μ opioid receptors would blunt OFC-dependent antidepressant placebo effects.

Methods: Twenty psychotropic-free patients with major depressive disorder completed a randomized, double-blind, placebo-controlled crossover study of 1 oral dose of 50 mg of naltrexone or matching placebo immediately before completing 2 sessions of the antidepressant placebo functional magnetic resonance imaging task. This task manipulates placebo-associated expectancies and their reinforcement while assessing expected and actual mood improvement.

Results: Behaviorally, manipulations of antidepressant placebo expectancies and their reinforcement had positive, interactive effects on participants' expectancy and mood ratings. The high-expectancy condition recruited the dorsolateral and ventrolateral prefrontal cortex, as well as dorsal attention stream regions. Interestingly, increased dorsolateral and ventrolateral prefrontal cortex brain responses appeared to attenuate the antidepressant placebo effect. The administration of 1 oral dose of naltrexone, compared with placebo, partially abolished the interaction of the expectancy and reinforcement manipulation on mood and blocked reinforcement-induced responses in the right central OFC.

Conclusions: Our results show preliminary evidence for the role of μ opioid central OFC modulation in antidepressant placebo effects by positively biasing the value of placebo based on reinforcement and enhancing subsequent hedonic experiences.

Citing Articles

The opioid system in depression.

Jelen L, Stone J, Young A, Mehta M Neurosci Biobehav Rev. 2022; 140:104800.

PMID: 35914624 PMC: 10166717. DOI: 10.1016/j.neubiorev.2022.104800.


Functional Neuroimaging Correlates of Placebo Response in Patients With Depressive or Anxiety Disorders: A Systematic Review.

Huneke N, Aslan I, Fagan H, Phillips N, Tanna R, Cortese S Int J Neuropsychopharmacol. 2022; 25(6):433-447.

PMID: 35078210 PMC: 9211006. DOI: 10.1093/ijnp/pyac009.

References
1.
Rush A, Gullion C, Basco M, Jarrett R, Trivedi M . The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996; 26(3):477-86. DOI: 10.1017/s0033291700035558. View

2.
Middaugh L, Bandy A . Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL/6 mice. Psychopharmacology (Berl). 2000; 151(4):321-7. DOI: 10.1007/s002130000479. View

3.
Groves S, Douglas K, Porter R . A Systematic Review of Cognitive Predictors of Treatment Outcome in Major Depression. Front Psychiatry. 2018; 9:382. PMC: 6121150. DOI: 10.3389/fpsyt.2018.00382. View

4.
Ponten M, Fust J, Kosek E, Guterstam J, Jensen K . Naltrexone during pain conditioning: A double-blind placebo-controlled experimental trial. Mol Pain. 2020; 16:1744806920927625. PMC: 7297482. DOI: 10.1177/1744806920927625. View

5.
Padoa-Schioppa C, Assad J . Neurons in the orbitofrontal cortex encode economic value. Nature. 2006; 441(7090):223-6. PMC: 2630027. DOI: 10.1038/nature04676. View